Application of chimeric antigen receptor-regulatory T cell immunotherapy in organ transplantation
10.3969/j.issn.1674-7445.2020.05.003
- VernacularTitle:嵌合抗原受体调节性T细胞免疫疗法在器官移植中的应用
- Author:
Yu WU
1
;
Peilu LI
;
Jun GE
;
Tingya JIANG
Author Information
1. AlloDx Biotech Co., LTD, Shanghai 215000, China
- Publication Type:Research Article
- Keywords:
Immunosuppressant;
Regulatory T cell (Treg);
Chimeric antigen receptor (CAR);
Antibody-mediated rejection (AMR);
Transplantation immune tolerance;
Donor specific antibody (DSA);
Human leukocyte antigen (HLA);
Graft-versus-host disease (GVHD)
- From:
Organ Transplantation
2020;11(5):547-
- CountryChina
- Language:Chinese
-
Abstract:
Regulatory T cell (Treg) is a subset of T cells that negatively regulates immunity and has the function of inhibiting rejection. The specific modification of Treg by chimeric antigen receptor (CAR) technology can successfully chime donor-specific antigen onto the surface of Treg, thus regulating the immune function of the body in a real-time manner. It provides a novel and promising therapeutic option for inducing immune tolerance. In this article, research progresses on Treg in immune related diseases, main difficulties in the realization of CAR-Treg technology and its role in inducing transplantation immune tolerance were reviewed, and the opportunities and challenges of CAR-Treg application in the field of organ transplantation are prospected.
